
COVID-19 candidate vaccine induces strong immune response; late-stage trial to start July 23
July 15 (UPI) -- U.S. biotech company Moderna said a vaccine it is developing has shown to induce a "rapid and strong" immune response against COVID-19, stating it will begin late-stage testing in less than two weeks. In a press release, the company said analysis of trial results for its potential COVID-19 vaccine "mRNA-1273" reaffirmed the "positive interim data assessment" it announced mid-May when the drug first showed a "potential to prevent" the deadly and infectious coronavirus. Advertisement During the trial, 45 healthy adult volunteers under 55 years of age were given two doses of the vaccine separated by 28 days with all participates who received doses of the drug in 100 micrograms or less reporting only mild, transient reactions such as fatigue, chills and headaches. The finding...